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Abstract
Synchrotron Microbeam Radiation Therapy (MRT) relies on the spatial fractionation of the synchrotron photon beam into
parallel micro-beams applying several hundred of grays in their paths. Several works have reported the therapeutic interest
of the radiotherapy modality at preclinical level, but biological mechanisms responsible for the described efficacy are not
fully understood to date. The aim of this study was to identify the early transcriptomic responses of normal brain and glioma
tissue in rats after MRT irradiation (400Gy). The transcriptomic analysis of similarly irradiated normal brain and tumor tissues
was performed 6 hours after irradiation of 9 L orthotopically tumor-bearing rats. Pangenomic analysis revealed 1012
overexpressed and 497 repressed genes in the irradiated contralateral normal tissue and 344 induced and 210 repressed
genes in tumor tissue. These genes were grouped in a total of 135 canonical pathways. More than half were common to
both tissues with a predominance for immunity or inflammation (64 and 67% of genes for normal and tumor tissues,
respectively). Several pathways involving HMGB1, toll-like receptors, C-type lectins and CD36 may serve as a link between
biochemical changes triggered by irradiation and inflammation and immunological challenge. Most immune cell
populations were involved: macrophages, dendritic cells, natural killer, T and B lymphocytes. Among them, our results
highlighted the involvement of Th17 cell population, recently described in tumor. The immune response was regulated by a
large network of mediators comprising growth factors, cytokines, lymphokines. In conclusion, early response to MRT is
mainly based on inflammation and immunity which appear therefore as major contributors to MRT efficacy.
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Introduction
Glioblastoma is the most aggressive form of brain tumor.
Despite the improvements in therapy [1] the median survival of
patients is around 12–15 months after diagnosis with a poor
survival rate of 9.8% beyond 5 years.
Synchrotron microbeam radiation therapy (MRT), a new form
of radiosurgery, has been applied to rodent brain tumors and
composed a new hope of treatment [2,3]. The use of highly intense
synchrotron X-ray beams, with a high energy, high flux and a
negligible divergence allows spatial fractionation of an incident
beam into arrays of few tens microns wide parallel microbeams,
delivering high radiation doses (hGy) in their paths and separated
by few hundred microns wide [4].
MRT protocol performed on the brains of adult rats [5],
suckling rats [6], ducks embryos [7] and piglets [8] highlighted a
sparing effect on normal tissues and can reduce the growth or
ablate EMT6 carcinoma [9], SCCVII carcinoma [10] and 9 L
intracerebral glioma [6,11–13].
It has been shown that the sparing effect is supported by the
radioresistance of normal brain vessels to MRT for doses up to
1,000Gy [14,15], while there is a denudation of the tumor
endothelium and a decrease in tumor blood volume [16,17].
Beyond the involvement of the vascular component, it has been
suggested that other processes were also responsible for tumor
control [17,18] and remain to be described and understood.
Besides, the effects of MRT have been studied at in vivo,
histological or cellular levels, but few information deals with
molecular mechanisms. Due to the unique irradiation geometry
and the extraordinary dose delivered by MRT, it is not reasonable
to extrapolate data and biological molecular events from
conventional radiotherapy studies without prior studies.
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Describing the early molecular events after MRT could
complete the understanding of the normal and tumor tissue
response to this particular irradiation. Microarray gene expression
technology allows simultaneous analysis of the expression levels of
thousands of genes [19]. It has been extensively used to describe
the response of biological entity to treatment, to assess genes
involved in resistance to therapy and to identify therapeutic targets
[20].
The purpose of this work was to characterize the early
transcriptomic responses of 9 L tumor and normal brain tissues
(contralateral half hemisphere) after a lateral unidirectional MRT
exposure (using 50 microns wide microbeams of 400Gy at the
tumor location, separated by 200 microns center-to-center). We
first illustrated the effectiveness of this single irradiation on the
survival of animals. Then, we used oligonucleotide microarray
containing 31,100 probe sets (28,000 genes) to acquire the
transcriptomic response of both 9 L glioma and contralateral
hemisphere 6 h after irradiation. Ingenuity Pathway Analysis
software allowed to underline biological functions and canonical
pathways involved in MRT response.
Materials and Methods
Ethics, animal care and study design
All procedures related to animal care conformed to the
Guidelines of the French Government under licenses 380325
and B3818510002 and were approved by the ESRF internal ethics
committee named ‘‘Internal Evaluation Committee for Animal
Welfare and Rights’’ (IECAWR). The committee specifically
approved this study.
All animals were Fischer male rats (Charles River, France) of 8
week-old at arrival. The 9 L cells were implanted one week after
the rat arrival (D0), and rats were allocated in two equilibrated
groups according tumor size measured using MRI 9 days after
implantation (D9). Rats were irradiated 10 days after implantation
(D10). The control animals (i.e. non-irradiated) were implanted in
common for two experiments including this one, in order to
reduce the number of animals.
First, two groups of rats were MRT-treated (n= 20) or not
(n = 9) and their survival was measured. Rats were observed and
weighted twice a week. They were humanely euthanized (intra-
cardiac injection of pentobarbital after isoflurane inhalation) when
previously defined clinical criteria were met (prostration, akinesy,
epistaxis, rotational motion, 25% body weight loss). In the second
part of the study aimed to define the molecular response to MRT,
two independent but similar experiments were performed: rats
were MRT-treated (n= 5 and n= 5) or not (n = 4 and n= 5) and
euthanized after 6 h for brain excision.
Rats were anesthetized with a shot of isoflurane 5% in air prior
to an intraperitoneal injection of xylazine/ketamine 64.5/
5.4 mg.kg21 for the implantation procedure (and local anesthesia
was performed by administration of lidocaine at the top of the
scalp) while they were maintained only under isoflurane 2.5% for
MRI examination and MRT irradiation. Ocry-gel (Carbopol) was
applied to avoid eye deshydration during any anesthesia.
Tumor implantation
The 9 L cells [20] were grown with complete medium
(DMEM/Fetal bovin serum 10%/Penicillin and Streptavidin
1%) at 37uC in a humidified 5% CO2 incubator. As previously
described [21], anesthetized Fischer rats were placed on a
stereotactic head holder. Then 104 9 L cells in 1 mL DMEM
were injected using a Hamilton syringe into the right caudate
nucleus (9 mm anterior to the ear-bars i.e. at bregma site, 3.5 mm
lateral to the midline, 5.5 mm depth from the skull).
Tumor MRI examination and rat randomization
Nine days after 9 L implantation, all rats underwent anatomical
MRI examination in order to sort them two groups with similar
mean tumor size. MRI was performed at 4.7 Tesla or 7 Tesla
(Avance III console; Bruker) of the Grenoble IRMaGe MRI
facility, using a horizontal magnet and a volume/surface cross coil
configuration applying a T2 weighted Turbo RARE SE sequence
(TE=33 ms, TR=4000 ms, field of view= 363 cm, matrix:
2566256, slice thickness = 1 mm). The height and width of
tumors were measured on the image where the signal modification
due to edema and tumor had the largest section. The 3rd direction
was estimated by counting the slices displaying the tumor.
MRT irradiation
Irradiations were performed at the ID17 Biomedical Beamline
of the European Synchrotron Radiation Facility (ESRF, France)
using X-rays emitted tangentially from electron bunches circulat-
ing in a storage ring. The wiggler produces a wide spectrum of
photons which extends, after filtration, from 50 over 350 keV
(median energy: 90 keV) [22]. The mean dose rate was then
,62Gy.mA21.s21 allowing very fast irradiation. The quasi-
laminar beam was micro-fractionated into an array of 41
rectangular and quasi-parallel 50 microns width microbeams,
separated by 200 microns center to center each. This was
performed by using the ESRF Multislit Collimator positioned
33 m from the photon source and 80 cm upstream from the rat
holder [23]. Ten days after tumor inoculation, the animals were
positioned prone on a Kappa-type goniometer (Huber, Germany)
in front of the x-rays source, on a home-made plexiglas frame and
the alignment into the beam was performed using live cameras.
The contention of the rats was performed by a teeth bar while the
animals were under anesthesia. They were placed perpendicularly
to the beam and received a lateral irradiation, from their
anatomical right to left side. The beam was shaped into a field
of irradiation of 8 mm horizontal and the animals were scanned
vertically over 10 mm through the beam after opening of the
shutter. Although the total procedure lasted about 2 min for each
rat, the irradiation time is around to 2 s. Animal immobility
during exposure was checked on three control video screens
located in the control hutch.
Dosimetry and ballistic of irradiation
The microbeam dose at the tumor (i.e. 7 mm of depth from
lateral side) was 400Gy, the valley dose was 1860.6Gy as
computed by Monte Carlo simulations [24]. The spatial config-
uration of irradiation was checked by radiochromic films
(Gafchromic, HD-810) exposed in front of rats. The conservation
of spatial configuration in tumor depth was checked by pH2AX
staining (double strand break indirect staining) on tissue sections
6 h after irradiation.
Survival curves
Kaplan Meier survival data of 9 untreated rats and 20 treated
rats was plotted versus time after tumor implantation. Median
Survival Time (MST) and statistical analysis (log rank test) were
performed using GraphPad Software, USA.
Brain excision
Untreated and MRT-treated rats (respectively n= 10 and n= 9)
were sacrificed 6 h after irradiation, and the brain of each animal
Transcriptomic Response to Synchrotron MRT
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was immediately frozen in liquid isopentane at 250uC and stored
at 280uC.
Total RNA extraction and quality control
For each brain, 25 coronal sections slices of 60 mm thick were
cut at 220uC on a cryostat (Microm HM80, France). The tumors
and the contralateral tissues were isolated using a micropunch and
kept in lysis RNAse free buffer from the MirVana isolation kitTM
(Ambion, Applied Biosystems, Foster City, CA).
Total RNA of each tissue was extracted with the previous kit
according to specifications. RNA integrity and concentration were
checked by Agilent NanoRNA Chip (Bio-Analyser, Agilent
Technologies, Palo Alto, CA, USA). A minimum RNA Integrity
Number of 7.6 was required for all samples.
RNA microarray
Microarray analysis were performed on total RNA of brain of
untreated (n= 5) and MRT-treated groups (n = 6) from two
experimental sessions (Figure 1). For each sample, 200 ng of total
RNA was amplified with the GeneChip 39IVT Express Kit
(Affymetrix, Santa Clara, CA) and hybridized on GeneChipH Rat
Genome 230 2.0 Array according to Affymetrix specifications.
Briefly, mRNAs were reverse transcribed to double stranded
cDNA, amplified, fragmented and biotin-labelled. End-label
cDNA were hybridized to microarray chip for 16 h at 45uC and
60rpm. After washing and staining in Affymetrix GeneChipH
Fluidics Station 450, microarrays were scanned using Affymetrix
GeneChipH Scanner 3000. Light emission at 570 nm is propor-
tional to each oligonucleotide amount on the GeneChipH array.
Gene expression normalization
Background adjustment and normalization of all raw probe
intensity were performed using the Robust Multi-array Average
(RMA) algorithm [25] implemented in Affymetrix Expression
Console. The expression values were reported in arbitrary units.
Moreover, the MicroArray Suite 5 (MAS5) algorithm [26] was
used on raw data to identify probe sets which were out of the limit
of detection for the system and to flag the transcript as Present (P)
or Absent (A). P- and A-flagged information was used to filter data
in order to remove false positive after statistical analysis.
Statistical analysis of microarray data
Statistical analysis was performed using the TIGR Multi-
Experiment Viewer version 4.5.1 software (TMeV, http://www.
tm4.org/mev/). Significant differentially expressed genes between
the two tumor groups and between the two contralateral tissue
groups (MRT treated or not) obtained 6 h after irradiation were
assessed using an unpaired Significance Analysis of Microarrays
(SAM) [27]. A False-Discovery Rate (FDR) lower than 5% was
fixed to generate significant genes list. Hierarchical clustering was
directly generated thanks to TMeV from this list. For all other
analyses, probes were only considered when at least n-1 values
were P-flagged (MAS5) in any of both compared groups.
Functional analysis
The molecular & cellular functions and canonical pathways
associated with differentially expressed genes identified by SAM
test (FDR 5%) and P/A flag filtered were identified thanks to
Ingenuity Pathways Analysis (IPA) software (IngenuityH Systems,
www.ingenuity.com). The data set was restricted to mammal
species.
Molecules from the data set were associated with the most
relevant ‘‘molecular & cellular functions’’ and ‘‘canonical path-
ways’’ in the Ingenuity Knowledge Base. The significance of the
association between the data set and the bio-function or the
canonical pathways was measured in 2 ways: 1) a ratio between the
number of molecules for a given function or pathway issued from
the data set and the total number of molecules for the same
function or pathway is displayed. 2) Right-tailed Fisher’s exact test
was used to calculate a p-value determining the probability that
each function or pathway assigned to that data set was due to the
chance alone. For canonical pathways, a false discovery rate of 1%
was further applied to correct for multiple testing [28,29].
RT-qPCR transcriptional validation for genes regulated
6 h after MRT
Some selected significantly up- and down-regulated genes were
validated using reverse transcription and quantitative polymerase
chain reaction (RT-qPCR) on untreated and MRT-treated tumor
samples (7,n,10, depending on sample availability).
Two micrograms of total RNA were transcribed into cDNA
using Promega Reverse Transcription reagents with random dN6
primers. Specific gene primers (Table 1) were designed using
software (https://www.roche-applied-science.com/sis/rtpcr/upl/
ezhome.html). Real-time PCR were performed according to the
SYBR Green method on an Mx3000TM apparatus (Stratagene, La
Jolla, CA) using Quantitect SYBH reagents (Qiagen, France). Data
were normalized using two housekeeping genes, Atp5b and
Arpc1a, selected according to Affymetrix data because of both
their suitable range of quantification and very low variation in
expression levels across all samples (8% and 7%, respectively).
Thermal-cycling parameters were as follows: denaturation at 95uC
for 10 min, cycling regime of 40 cycles at 95uC for 15 s, 56uC for
30 s, and 72uC for 30 s.
Results
Survival
In order to obtain similar irradiation in tumor and normal
contralateral brain tissue, we have adapted a configuration of
MRT previously reported to have a high interest for 9 L brain
tumors therapy [17]. As shown in figure 2, this unilateral MRT
irradiation significantly increased the Mean Survival Time (MST)
of treated animals compared with the untreated group (33 versus
19 days respectively, p,0.0001).
Identification of early gene response in 9 L tumor and
contralateral brain tissue
Six hours after irradiation, we observed (i) a modification of
transcriptomic profiles in both tissues and (ii) a difference in
responses of tumor and contralateral tissues (Figure 3a and b).
Indeed, 1,509 genes (1,012 were induced and 497 were inhibited)
Figure 1. Experimental scheme. Contralateral normal and tumor
tissue samples were irradiated (MRT) or not (untreated) in 2
experimental sessions (S1 and S2). The transcriptomic data were
compared in order to determine contralateral normal and tumor tissue
responses to MRT (D normal tissue or D tumor tissue).
doi:10.1371/journal.pone.0081874.g001
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and 554 genes (344 were induced and 210 were inhibited)
significantly responded to MRT in tumor and contralateral tissues,
respectively (Figure 3c and Table S1). Figures 3a and 3b show the
clustering analysis based on the selected genes in contralateral and
tumor tissues respectively. Among them, 319 were common to
both tissues as represented on Venn diagram (227 were induced
and 92 were inhibited).
Validation of gene expression modulation by RT-qPCR
We validated the variation of gene expression by quantitative
RT-PCR on 6 representative genes with significant expression
modulation in tumor. RT-qPCR analysis was performed on tissues
that had been already analyzed on microarray and extended on
supplementary tumors (in all n$7). The RT-qPCR results
confirmed that expression of all selected genes was significantly
different between treated and untreated tumors (p,0.05, permu-
tation t-test) and were therefore consistent with those obtained by
microarrays (Figure 4).
Identification of biological functions modulated in 9 L
tumor and contralateral brain tissues 6 hours after MRT
Genes identified by SAM analysis with a 5% FDR were
classified into different bio-function categories based on IPA
database (Figure 5). The response to MRT irradiation involved 22
and 18 molecular and cellular functions in tumor and normal
brain tissues, respectively. All functions found in contralateral
tissue were also represented in tumor tissue. Some bio-function
categories such as cell death, growth, proliferation, cell cycle,
cellular function and maintenance can contribute to cell response
to radiation-induced damages. Inflammation and immunity
reaction appeared as a common point of cellular movement,
antigen presentation and cell-to-cell signaling/interaction catego-
ries. Despite a lower number of genes per group, tumor response
to MRT displayed four supplemental bio-functions compared to
normal tissue: amino acid metabolism (p = 7.02e206), carbohy-
drate metabolism (p = 2.44e205), drug metabolism (p= 7.02e206)
and nucleic acid metabolism (p= 4.55e206). These 4 bio-functions
showed the lowest p-value obtained for MRT response in tumor
(Figure 5).
Identification of pathways modulated in 9 L tumor and
contralateral brain tissues 6 hours after MRT
Genes modulated 6 hours after MRT in tumor and contralat-
eral tissues were grouped in canonical pathways (Table S2). Three
statistical stringency levels were applied to data with 5, 1 and 0.1%
of False Discovery Rate (FDR), corresponding to p-values lower to
1.62E-2, 2.57E-3 and 1.45E-4 respectively. The number of
pathways ranged from 83 (FDR0.1%) to 165 (FDR5%) in
contralateral brain, from 36 to 100 in tumor and from 86 to
170 when both tissues were considered together. Pathways were
more numerous for brain than for tumor (.1.6), as already
observed for modulated genes. For all FDRs, more than half of all
pathways were found in both tissues (55.3% for FDR5%, 50.4%
for FDR1% and 73.3% for FDR0.1%). So the response to MRT
appeared to mainly involve similar mechanisms in normal brain
and tumor. More, whatever the tissue or the FDR, pathways
related to immunity or inflammation represented more than 55%
of the total (from 55.8 for brain and tumor tissue with FDR5% to
74.4% for brain and tumor tissue with FDR0.1%). Thus the
response to MRT was mainly based on these two processes. The
pathways related to immunological or inflammatory responses
were enriched in the most stringent statistical conditions,
illustrating that these pathways are among the most significant
ones.
We focused analysis on pathways with FDR1%. Genes
modulated by MRT were grouped on 128 pathways in normal
brain, 73 in tumor and 67 were common to both tissues. Among
them, 82 and 49 pathways were related to immunity or
Table 1. Validation gene set.
Symbol Gene Name Forward (59-39) Reverse Primer (59-39)
Arpc1a actin related protein 2/3 complex, subunit 1A gtttgctgtggggagtgg ggatcggcttcttaatgtgc
Atp5b ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide gggtacaatgcagga tcagctggcacatag
Fam64a family with sequence similarity 64, member A gaagctgtctcaaaagctgga aagggagacggtcatgtcac
Inhbe inhibin beta E caggcagcactgaccaga gcggtaggttgaagtggatt
Mars mehionine-tRNA synthetase atacgttcggtcgcacaac gcaacctctggaagatgtcc
Traf4af1 TRAF4 associated factor 1 cggaggaacatcagaagcag gctcgtttttatccttcagatcc
Pttg1 pituitary tumor-transforming 1 ttcttccccttcgatcctct aggggagaagtgagatctggt
Trib3 tribbles homolog 3b tcaagttgcgtcgatttgtc ccagtcatcacacaggcatc
List of the genes with significant up- or down-regulation which were selected for microarray data validation using RT-qPCR. Primer sequences for quantitative RT-qPCR
are indicated in the two right-hand columns.
doi:10.1371/journal.pone.0081874.t001
Figure 2. Kaplan-Meier representation of tumor-bearing rat
survival. Intracerebral 9 L rats were MRT-irradiated (solid black line) or
not (dashed grey line). MRT significantly increased the Median Survival
Time of animals compared with untreated rats (33 days versus 19 days,
log rank test: p,0.0001).
doi:10.1371/journal.pone.0081874.g002
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Figure 3. Influence of MRT on gene expression in tumor and contralateral brain tissues. a, b- Heat map showing either significant
decrease or increase in mRNA expression after MRT in tumor and normal brain tissues. Colors indicate expression levels above (red) or below (green)
the median value for each gene. Vertical columns indicate individual arrays and horizontal rows indicate genes. c- Venn diagrams showing the
numbers of significantly increased (red) or decreased (green) genes after MRT in both tissues.
doi:10.1371/journal.pone.0081874.g003
Figure 4. Validation of microarray analysis by quantitative RT-PCR on tumor tissue samples. Data were first normalized to the expression
of Arpc1 and Atp5b housekeeping genes. The fold changes (6SEM) in each gene expression was calculated using the mean expression in treated
(n = 6 for microarray and n=8 to 9 for RT-qPCR) versus untreated (n = 5 for microarray and n= 7 to 10 for RT-qPCR) tumors 6 h after MRT. Fold
changes are indicated below the histograms (several fold changes were available for microarray because of the presence of several probesets). All
tested genes presented a significant difference between treated and untreated tissues (p,0.05; permutation t-test).
doi:10.1371/journal.pone.0081874.g004
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inflammation in normal brain and tumor respectively. Forty six
immune-relative pathways were common to both tissues; however
they could include different genes for tumor and contralateral
tissues (Figure 5).
All domains of innate and adaptive immunity were found in
common canonical functions: macrophages (‘‘Role of Macrophag-
es, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis’’,
‘‘Production of Nitric Oxide and Reactive Oxygen Species in
Macrophages’’, ‘‘IL-12 Signaling and Production in Macrophag-
es’’), natural killer cells (NK, ‘‘Crosstalk between Dendritic Cells
and Natural Killer Cells’’), dendritic cells (‘‘Dendritic Cell
Maturation’’, ‘‘Crosstalk between Dendritic Cells and Natural
Killer Cells’’), T lymphocytes (‘‘Altered T Cell and B Cell
Signaling in Rheumatoid Arthritis’’, ‘‘iCOS-iCOSL Signaling in T
Helper Cells’’, ‘‘4-1BB Signaling in T Lymphocytes’’) and B
lymphocytes (‘‘Altered T Cell and B Cell Signaling in Rheumatoid
Arthritis’’ and ‘‘B Cell Receptor Signaling’’, ‘‘PI3K Signaling in B
Lymphocytes’’, ‘‘B Cell Activating Factor Signaling’’). Many
canonical pathways and especially those centered on cytokines
signaling, evoked also the immune network: Interleukins 1, 6, 8, 9,
10, 12, 15, 17A and 17F were found in 13 pathways. Immune cell
communication was illustrated by other either mediators or
receptors: TNF (‘‘TWEAK Signaling’’, ‘‘April Mediated Signal-
ing’’, ‘‘4-1BB signaling in T Lymphocytes’’), Interferon (‘‘Role of
PKR in Interferon Induction and Antiviral Response’’, ‘‘Role of
JAK1, JAK2 and TYK2 in Interferon signaling’’) and others
(‘‘iCOS-iCOSL Signaling in T Helper Cells’’, ‘‘MIF Regulation of
Innate Immunity’’, ‘‘CD40 Signaling’’). As expected, inflamma-
tion was found (‘‘Acute Phase Response Signaling’’, ‘‘TREM1
Signaling’’, ‘‘Atherosclerosis Signaling’’, ‘‘Role of IL-17F in
Allergic Inflammatory Airway Diseases’’, ‘‘Pathogenesis of Mul-
tiple Sclerosis’’, ‘‘Role of IL-17A in Arthritis’’, ‘‘MIF-mediated
Glucocorticoid Regulation’’, ‘‘Glucocorticoid Receptor Signal-
ing’’).
Figure 5. Molecular and cellular functions constituting the MRT response. Genes with a significantly modified expression in brain or tumor
6 hours after MRT were clustered in molecular and cellular function using IPA software. Number of genes and p-values (2log(p-value)) are illustrated
for each function. The p-values associated with brain (dark blue) and tumor (light blue) are represented using histogram in the right-hand column.
The p-values were calculated using the right-tailed Fisher’s exact test in IPA.
doi:10.1371/journal.pone.0081874.g005
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The common response to MRT comprised also modifications in
the expression of genes involved in other mechanisms: Cell cycle,
cell growth, apoptosis (‘‘Induction of Apoptosis by HIV1’’,
‘‘Apoptosis Signaling’’, ‘‘Death Receptor Signaling’’, ‘‘p38 MAPK
Signaling’’, ‘‘p53 Signaling’’, ‘‘PI3K/AKT Signaling’’), DNA
damage sensing and repairing (‘‘ATM Signaling’’) and vascular
physiology or angiogenesis (‘‘Erythropoietin Signaling’’, ‘‘Renin-
Angiotensin Signaling’’, ‘‘Angiopoietin Signaling’’).
In normal brain, other pathways for cell cycle/growth or
apoptosis (‘‘Cell Cycle Regulation by BTG Family Proteins’’,
‘‘ERK/MAPK Signaling’’, ‘‘PTEN Signaling’’), DNA damage
sensing or repairing (‘‘Role of BRCA1 in DNA Damage
Response’’) and vascular physiology and angiogenesis (‘‘Role of
Tissue Factor in Cancer’’) were found.
Of interest, in tumor tissue, we found one pathway associated
with both DNA damage and cell cycle regulation (‘‘Cell Cycle:
G2/M DNA Damage Checkpoint Regulation’’).
A part of pathways were found in only one tissue. Concerning
normal brain, a high proportion of pathways related to T-cells
(15/49) was observed in comparison with those found in both
tissues (6/46). On the opposite, only 4 pathways were preferen-
tially associated with innate immunity in normal brain tissue.
Discussion
In this work we characterized the transcriptomic responses of
tumor and normal brain tissues 6 hours after an MRT irradiation.
A suitable model should heed following parameters: both tissues
should originate from the same species in order to use a unique
microarray type for transcriptome analysis, and host animal
should be immunocompetent for considering the influence of the
immune system. The 9 L tumors orthotopically implanted in
syngeneic Fisher rat brain fulfill these conditions [20,30].
MRT has already been demonstrated as a promising irradiation
modality for brain tumors therapy at preclinical level. Although
MRT crossfire irradiation, the most efficient configuration for
improving survival to date [6], implies that the tumor and the
contralateral brain tissues are not treated the same way. We chose
therefore a simpler configuration with a lateral unidirectional
MRT irradiation in order to apply similar irradiation configura-
tion in both tissues. This 400Gy in-microbeam dose scheme,
applied to rat brain 10 days after tumor inoculation, significantly
increased (61.7) the median survival time (MST) compared to
untreated rats (Figure 2). The set parameters enable then a
rigorous analysis of biological mechanisms of MRT impact in both
tumor and normal brain tissue responses. Although several studies
already aimed at the understanding of biological processes induced
by MRT, they were essentially based on late events (from 48 h
post-MRT) [16,17]. In this work we focused on early response,
assuming that early transcriptomic events would dictate later
modifications at molecular, cellular, tissular and finally therapeutic
levels. We considered also the particular lack of knowledge
concerning MRT-associated biology at transcriptomic level.
MRT differs from conventional irradiation because it delivers
several hundreds of grays in micrometric volumes in few seconds
with a particular geometry, which might influence the gene
expression response. Due to recent improvements in theoretical
and experimental dosimetry [31] experiments involving broad
beam irradiation with synchrotron sources are currently in
progress in our laboratory to determine the impact of the complex
irradiation scheme of MRT. Although a similar study has been
done in Boomerang (Melbourne, Australia) [32], the experimental
parameters such as the source, the MRT parameters, the tumor
model differ than ours.
We determined the pan-genomic response of both tumor and
normal brain tissues 6 h after MRT by using microarrays
containing 31,000 probesets. In normal brain tissue the expression
of about 5% of genes was modified. This proportion is higher than
those described using other methods after ionizing irradiation of
brain (0.6% 8 h after 10Gy [33], 1.1% and 2.2% 5 h after 10Gy
and 20Gy [34]) but is consistent with a previously reported dose-
dependent increase in both expression level and number of
modulated genes [34–36]. So the unusual number of engaged
genes after MRT could be linked to the high dose deposited in
tissue, from ,18Gy in valleys to 400Gy in microbeams.
In tumor 1.8% of genes were modified. To our knowledge, no
microarray analysis was performed in 9 L after irradiation and
those conducted on other high grade glioma models were very
different to ours in number of analysed genes, type and dose of
irradiation. The unique comparable study applied to MRT was
performed on EMT6 subcutaneous mammary tumor [32]. It
revealed the modulation of 184 genes but did not address the
response of normal tissue.
The response to MRT of normal brain tissues involved 2.7
times more genes than the one of tumor tissue (1,509 versus 554),
revealing a tissue-specific response to MRT (Figure 3 and Table
S1). Such a higher number of genes could arise from the higher
cellular diversity of normal tissue, due to the presence of specific
parenchymal and stromal cells such as neurons, astrocytes and
oligodendrocytes. Surprisingly these genes were associated with
less molecular and cellular functions in normal (18 functions)
compared with tumor tissue (22 functions; Figure 5). The 4
supplementary functions in tumor were associated with metabolic
processes. However they displayed the lowest statistical signifi-
cance for tumor response. Responses of both tissues appeared
therefore to be close to each other since 18 functions were
common. Moreover, a modulation of genes involved in mitosis,
cell cycle regulation, apoptosis, cell adhesion, glycolysis, lipid
metabolism, has already been reported after ionizing radiation
[37] and could be connected to many functions implicated in the
response of the both tissue after MRT.
A large number of canonical pathways were also identified 6 h
after MRT: 128 and 73 in tumor and contralateral tissues,
respectively (Table S2). Among them, 67 were common. More
than 90% of canonical pathways found in tumor were also found
in brain (only 6 specific pathways out of 73), while 52.3% of
normal brain pathways were found in tumor. Thus the tumor
response to MRT was mostly included in the brain tissue one.
Again, this result could reflect a higher heterogeneity in cell
composition and functional processes in normal brain compared to
tumor.
Of interest, we observed only one canonical pathway related to
brain parenchyma response to MRT (‘‘Huntington’s disease
signaling’’) which includes genes related to apoptosis (Caspase 1,
3, 7, 8, 12, bax, TP53), intracellular signaling (GNG2, GNG11,
CREB3, PRKCH, PRKCD) and one is neuron-specific (CAC-
NA1B). This canonical pathway suggests that some neurons
undergo apoptosis in response to MRT.
Among the 67 common pathways to both tissues, immunity and
inflammation were widely represented. Modulation of immunity
and inflammation has been often reported in brain in response to
various stimuli or injuries: Presence of a tumor mass, radiotherapy
[38], bacterial or viral infection [39], neurodegenerative disorders
such as Alzheimer’s and Parkinson’s diseases ([40,41]).
But our results are also in agreement with previous works which
reported the immune activation in response to conventional
irradiation and even considered irradiation as an ‘‘immunological
adjuvant’’ [38,42–44]. Concerning MRT, previous works mainly
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focused on vascular parameters to explain therapeutic effect [17].
However increasing leukocytes recruitment was observed in both
normal brain [45] and 9 L tumor tissues [17]. Moreover, Sprung et
al. recently reported that modifications in immunity-related gene
expression is a hallmark of response to MRT in mouse mammal
tumor [32].
Gasser et al. [46] reported that DNA damage can elicit a
response of immune system, and in particular of innate
compartment (macrophages). But other normal cells constituents
can be released into the extracellular compartment during states of
cellular stress or damage and subsequently activate inflammation
and immunity. Among these Damage-Associated Molecular
Patterns, we found HMG1 that is both involved in infectious
and sterile inflammation, immune response and tissue repair or
regeneration [47]. Receptors such as Toll-like receptors, C-type
lectins are sensing these damage-associated mediators. Indeed, we
observed a modulation in the expression of several potential
mediators and receptors involved in the simulation of inflamma-
tion or immunity. For example, HMGB1, Toll-like receptors 1, 2,
7, C-type lectins 7A and CD36 and other altered constituents of
irradiated tissue can trigger activation of innate or adaptive cells.
These genes may serve as a link between biochemical changes in
response to irradiation and the inflammation or immunological
challenge.
We evidenced subsequently to this activation that most
populations of the immunological compartment were triggered
(macrophages, natural killer, dendritic cells, T and B lymphocytes)
and many direct crosstalks between cells or diffusible mediators
highlighted communication between them.
Dendritic cells constitute the first line of the adaptive immune
response, as antigen-presenting cells. Maturation of dendritic cells
has been reported to be impaired in cancer in response to tumor-
derived mediators, especially the Vascular Endothelial Growth
Factor [48]. However the modulation of the pathway ‘‘maturation
of dendritic cells’’ in our study suggests that dendritic cell
maturation occurred in response to MRT, likely as a part of the
‘‘immunological adjuvant’’ phenomenon discussed above. This
would participate in enhancing efficiency of immune control of
cancer progression.
We observed also at transcriptomic level the recruitment of
innate immune compartment. Presence of Natural killer (NK) was
indicated in our study by the modulation of two canonical
pathways (‘‘Crosstalk between Dendritic Cells and Natural Killer
Cells’’, ‘‘Tumoricidal Function of Hepatic Natural Killer Cells’’)
and could be a crucial point for MRT efficiency since NK were
previously shown to eliminate 9 L glioma cells both in vitro [49]
and in vivo [50,51].
Among the large spectrum of diffusible mediators, one of them,
IL-17 is specifically expressed by T helper 17 cells (Th17; [51]).
The presence of these cells was reinforced by modifications in
expression of IL-6, IL-23, STAT3, ICOS. These cells are key
mediators of a broad array of inflammatory or autoimmune
diseases and have been extensively found in tumor microenviron-
ment [52]. But their positive or negative role in tumor progression
is still debated. The recruitment of Th17 cells was reported to be
triggered by local inflammation at the tumor site [53]. One can
hypothesize that irradiation could increase inflammation and
therefore Th17 cell recruitment.
Our transcriptomic results also indicate the presence of
cytotoxic T cells (‘‘Cytotoxic T Lymphocyte-mediated Apoptosis
of Target Cells’’ (Table S2). In parallel with NK cells, cytotoxic T
cells were heavily reported in immunological antitumor phenom-
enon. Cytotoxic T cells have been associated with spontaneous
tumoricidal action on glioma and emerged as a part of some
therapeutic strategies. For example, vaccination of rats with
dendritic cells coinjected with processed GM-CSF secreting 9 L
cells triggered the regression of distant 9 L tumors [54]. Treatment
efficacy was associated with a Th1 response and thus IFNc
secretion [55]. IFNc appears also in several canonical pathways
modified by MRT in our study (Table S2).
In conclusion to this work we report an extended gene
expression profile associated with the MRT responses in both
normal and tumor tissues. The early transcriptomic response is
very similar in both tissues, mainly involves modifications
associated with immunity and inflammation. The detailed study
of pathways modulated by MRT reveals the involvement of
transcriptomic modification in relation with innate and/or the
adaptative immune response. More specifically, pathways and
biofunction in link with NK or CD8+ T lymphocytes are
particularly reprensented. Further immunological studies and
functional analysisare needed for evaluating the role of those
immune mechanisms in the therapeutic impact of irradiation. This
is an important step for understanding the biological mechanisms
responsible for the therapeutic index of the MRT.
Supporting Information
Table S1 Genes responding significantly to MRT in
tumor and normal brain tissues. List of all genes which
expression is significantly modified in brain (1,509 genes) and
tumor (554 genes). Probesets are ranked for each tissue in
descending order of expression MRT/untreated ratio.
(XLSX)
Table S2 Canonical pathways constituting the MRT
response. All canonical pathways (IPA) found statistically
significant with 1% FDR (corresponding to p-value lower than
2.57E-3) are listed for both normal and tumor tissues.
(XLSX)
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